An official website of the United States government
Home
Name
Zanubrutinib
Alternate Names
BRUKINSA
Abbreviations
None
Category
Chemotherapy
Subcategory
Bruton's tyrosine kinase inhibitor
NSC Number
None
Primary Site
None
Histology
Remarks
March 7, 2024 FDA granted accelerated approval to zanubrutinib (Brukinsa) with obinutuzumab for relapsed or refractory follicular lymphoma (FL) after two or more lines of systemic therapy.
January 27, 2023 FDA approved Brukinsa (zanubrutinib) for chronic lymphocytic leukemia or small lymphocytic lymphoma.
August 31, 2021 The FDA approved zanubrutinib (Brukinsa) for adult patients with Waldenström’s macroglobulinemia (WM).
Sept. 24, 2021 Brukinsa (zanubrutinib) has received FDA accelerated approval for adult patients with relapsed or refractory marginal zone lymphoma (MZL) who have received at least one anti-CD20- based regimen.
November 14, 2019 FDA granted accelerated approval to zanubrutinib (BRUKINSA) for adult patients with mantle cell lymphoma (MCL) who have received at least one prior therapy.
January 27, 2023 FDA approved Brukinsa (zanubrutinib) for chronic lymphocytic leukemia or small lymphocytic lymphoma.
August 31, 2021 The FDA approved zanubrutinib (Brukinsa) for adult patients with Waldenström’s macroglobulinemia (WM).
Sept. 24, 2021 Brukinsa (zanubrutinib) has received FDA accelerated approval for adult patients with relapsed or refractory marginal zone lymphoma (MZL) who have received at least one anti-CD20- based regimen.
November 14, 2019 FDA granted accelerated approval to zanubrutinib (BRUKINSA) for adult patients with mantle cell lymphoma (MCL) who have received at least one prior therapy.
Coding
This drug should be coded
